
Opinion|Videos|July 12, 2024
Evaluating Value of BTK Inhibitors in CLL Treatment
Experts evaluate the value of BTK inhibitors in CLL treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
3
Contributor: Why Public Health Keeps Failing—and How to Fix It
4
Aumolertinib Effective in Treating EGFR-Mutant NSCLC
5